© Reuters. GSK logo is seen in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration
(Reuters) – Britain’s GlaxoSmithKline (NYSE:) has agreed to buy California-based biopharmaceutical company Sierra Oncology (NASDAQ:) in a deal valued at $1.9 billion, the companies said on Wednesday.
Shareholders in Sierra, which focuses on targeted therapies for the treatment of rare forms of cancer, will receive $55 per share of common stock in cash, GSK said.
Be the first to comment